JP2014526499A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014526499A5 JP2014526499A5 JP2014530361A JP2014530361A JP2014526499A5 JP 2014526499 A5 JP2014526499 A5 JP 2014526499A5 JP 2014530361 A JP2014530361 A JP 2014530361A JP 2014530361 A JP2014530361 A JP 2014530361A JP 2014526499 A5 JP2014526499 A5 JP 2014526499A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- pharmaceutically acceptable
- triazolo
- pyrazol
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims description 40
- 150000001875 compounds Chemical class 0.000 claims description 24
- 125000000623 heterocyclic group Chemical group 0.000 claims description 24
- -1 1-methyl-1H-pyrazol-4-yl Chemical group 0.000 claims description 23
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 239000001257 hydrogen Substances 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 125000001153 fluoro group Chemical group F* 0.000 claims description 6
- 239000013543 active substance Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- RQZASYHLVWNLOK-UHFFFAOYSA-N 1-[6-[[6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]quinolin-3-yl]piperidin-4-ol Chemical compound C1=NN(C)C=C1C1=CN2C(SC=3C=C4C=C(C=NC4=CC=3)N3CCC(O)CC3)=NN=C2C=C1 RQZASYHLVWNLOK-UHFFFAOYSA-N 0.000 claims description 3
- OCUFWFWPMTVLOB-CALCHBBNSA-N 3-[(3s,5r)-3,5-dimethylpiperazin-1-yl]-6-[[6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]quinoline Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=CN=C(C=CC(SC=2N3C=C(C=CC3=NN=2)C2=CN(C)N=C2)=C2)C2=C1 OCUFWFWPMTVLOB-CALCHBBNSA-N 0.000 claims description 3
- URAMORWCRRAYRG-UHFFFAOYSA-N 4-[6-[[6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]quinolin-3-yl]morpholine Chemical compound C1=NN(C)C=C1C1=CN2C(SC=3C=C4C=C(C=NC4=CC=3)N3CCOCC3)=NN=C2C=C1 URAMORWCRRAYRG-UHFFFAOYSA-N 0.000 claims description 3
- GGSJKYXMTHZWFU-UHFFFAOYSA-N 4-[6-[[8-fluoro-6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]quinolin-3-yl]morpholine Chemical compound C1=NN(C)C=C1C1=CN2C(SC=3C=C4C=C(C=NC4=CC=3)N3CCOCC3)=NN=C2C(F)=C1 GGSJKYXMTHZWFU-UHFFFAOYSA-N 0.000 claims description 3
- ZRUDAHOWOHKQAO-UHFFFAOYSA-N 6-[[8-fluoro-6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]-3-(4-methoxypiperidin-1-yl)quinoline Chemical compound C1CC(OC)CCN1C1=CN=C(C=CC(SC=2N3C=C(C=C(F)C3=NN=2)C2=CN(C)N=C2)=C2)C2=C1 ZRUDAHOWOHKQAO-UHFFFAOYSA-N 0.000 claims description 3
- 230000004968 inflammatory condition Effects 0.000 claims description 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 3
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- PUWKUQQXKAHOFP-UHFFFAOYSA-N 1-[6-[[8-fluoro-6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]quinolin-3-yl]piperidin-4-ol Chemical compound C1=NN(C)C=C1C1=CN2C(SC=3C=C4C=C(C=NC4=CC=3)N3CCC(O)CC3)=NN=C2C(F)=C1 PUWKUQQXKAHOFP-UHFFFAOYSA-N 0.000 claims description 2
- UJHKEEXPTFPJNG-UHFFFAOYSA-N 3-(4-methoxypiperidin-1-yl)-6-[[6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]quinoline Chemical compound C1CC(OC)CCN1C1=CN=C(C=CC(SC=2N3C=C(C=CC3=NN=2)C2=CN(C)N=C2)=C2)C2=C1 UJHKEEXPTFPJNG-UHFFFAOYSA-N 0.000 claims description 2
- GUQCOZKYQUTLJM-UHFFFAOYSA-N 3-(4-methylpiperazin-1-yl)-6-[[6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]quinoline Chemical compound C1CN(C)CCN1C1=CN=C(C=CC(SC=2N3C=C(C=CC3=NN=2)C2=CN(C)N=C2)=C2)C2=C1 GUQCOZKYQUTLJM-UHFFFAOYSA-N 0.000 claims description 2
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- XELQJFZPZDIESZ-UHFFFAOYSA-N 6-[[8-fluoro-6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]-3-(4-methylpiperazin-1-yl)quinoline Chemical compound C1CN(C)CCN1C1=CN=C(C=CC(SC=2N3C=C(C=C(F)C3=NN=2)C2=CN(C)N=C2)=C2)C2=C1 XELQJFZPZDIESZ-UHFFFAOYSA-N 0.000 claims description 2
- OJMCEDPZTBVMKX-IYBDPMFKSA-N 3-[(3r,5s)-3,5-dimethylpiperazin-1-yl]-6-[[8-fluoro-6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]quinoline Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=CN=C(C=CC(SC=2N3C=C(C=C(F)C3=NN=2)C2=CN(C)N=C2)=C2)C2=C1 OJMCEDPZTBVMKX-IYBDPMFKSA-N 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 27
- 125000004433 nitrogen atom Chemical group N* 0.000 description 19
- 229920006395 saturated elastomer Polymers 0.000 description 14
- 125000001424 substituent group Chemical group 0.000 description 11
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 125000005843 halogen group Chemical group 0.000 description 8
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 description 6
- 125000004430 oxygen atom Chemical group O* 0.000 description 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000004548 quinolin-3-yl group Chemical group N1=CC(=CC2=CC=CC=C12)* 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- INPAZULREKEJFI-IBGZPJMESA-N (3s)-1-[6-[[8-fluoro-6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]quinolin-3-yl]-n,n-dimethylpyrrolidin-3-amine Chemical compound C1[C@@H](N(C)C)CCN1C1=CN=C(C=CC(SC=2N3C=C(C=C(F)C3=NN=2)C2=CN(C)N=C2)=C2)C2=C1 INPAZULREKEJFI-IBGZPJMESA-N 0.000 description 1
- JFUJCFQHJLAUFM-IBGZPJMESA-N (3s)-n,n-dimethyl-1-[6-[[6-(1-methylpyrazol-3-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]quinolin-3-yl]pyrrolidin-3-amine Chemical compound C1[C@@H](N(C)C)CCN1C1=CN=C(C=CC(SC=2N3C=C(C=CC3=NN=2)C2=NN(C)C=C2)=C2)C2=C1 JFUJCFQHJLAUFM-IBGZPJMESA-N 0.000 description 1
- ZYPGNMBTYZEVSF-AFUMVMLFSA-N (ne)-n-[1-[3-(3-morpholin-4-ylquinolin-6-yl)sulfanyl-[1,2,4]triazolo[4,3-a]pyridin-6-yl]ethylidene]hydroxylamine Chemical compound N12C=C(C(=N/O)/C)C=CC2=NN=C1SC(C=C1C=2)=CC=C1N=CC=2N1CCOCC1 ZYPGNMBTYZEVSF-AFUMVMLFSA-N 0.000 description 1
- PSNYRIOHVUOFPW-FLOSOGMCSA-N (ne)-n-[1-[3-[3-[(3s)-3-(dimethylamino)pyrrolidin-1-yl]quinolin-6-yl]sulfanyl-[1,2,4]triazolo[4,3-a]pyridin-6-yl]ethylidene]hydroxylamine Chemical compound C1[C@@H](N(C)C)CCN1C1=CN=C(C=CC(SC=2N3C=C(C=CC3=NN=2)C(\C)=N\O)=C2)C2=C1 PSNYRIOHVUOFPW-FLOSOGMCSA-N 0.000 description 1
- ZTEMQDXNBKSGLA-UHFFFAOYSA-N 1-[6-[[6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]quinolin-3-yl]piperidin-3-amine Chemical compound C1=NN(C)C=C1C1=CN2C(SC=3C=C4C=C(C=NC4=CC=3)N3CC(N)CCC3)=NN=C2C=C1 ZTEMQDXNBKSGLA-UHFFFAOYSA-N 0.000 description 1
- RFBXKLIIPVQMDB-UHFFFAOYSA-N 1-[6-[[6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]quinolin-3-yl]piperidin-4-amine Chemical compound C1=NN(C)C=C1C1=CN2C(SC=3C=C4C=C(C=NC4=CC=3)N3CCC(N)CC3)=NN=C2C=C1 RFBXKLIIPVQMDB-UHFFFAOYSA-N 0.000 description 1
- OBLFFFKSZZMQJH-UHFFFAOYSA-N 1-[6-[[6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]quinolin-3-yl]pyrrolidin-3-amine Chemical compound C1=NN(C)C=C1C1=CN2C(SC=3C=C4C=C(C=NC4=CC=3)N3CC(N)CC3)=NN=C2C=C1 OBLFFFKSZZMQJH-UHFFFAOYSA-N 0.000 description 1
- ZXABHOBAANBQOO-LQKURTRISA-N 1-[6-[[6-[(e)-n-(2-hydroxyethoxy)-c-methylcarbonimidoyl]-[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]quinolin-3-yl]piperidin-4-ol Chemical compound N12C=C(C(=N/OCCO)/C)C=CC2=NN=C1SC(C=C1C=2)=CC=C1N=CC=2N1CCC(O)CC1 ZXABHOBAANBQOO-LQKURTRISA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- JEWZQZFYIBRIBC-UHFFFAOYSA-N 2,6-dimethyl-4-[6-[[6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]quinolin-3-yl]morpholine Chemical compound C1C(C)OC(C)CN1C1=CN=C(C=CC(SC=2N3C=C(C=CC3=NN=2)C2=CN(C)N=C2)=C2)C2=C1 JEWZQZFYIBRIBC-UHFFFAOYSA-N 0.000 description 1
- STWYWDMBNVHQIZ-JVWAILMASA-N 2-[(e)-1-[3-(3-morpholin-4-ylquinolin-6-yl)sulfanyl-[1,2,4]triazolo[4,3-a]pyridin-6-yl]ethylideneamino]oxyethanol Chemical compound N12C=C(C(=N/OCCO)/C)C=CC2=NN=C1SC(C=C1C=2)=CC=C1N=CC=2N1CCOCC1 STWYWDMBNVHQIZ-JVWAILMASA-N 0.000 description 1
- IYSRDIPKAXCGSE-XSZJBBQGSA-N 2-[(e)-1-[3-[3-[(3s)-3-(dimethylamino)pyrrolidin-1-yl]quinolin-6-yl]sulfanyl-8-fluoro-[1,2,4]triazolo[4,3-a]pyridin-6-yl]ethylideneamino]oxyethanol Chemical compound C1[C@@H](N(C)C)CCN1C1=CN=C(C=CC(SC=2N3C=C(C=C(F)C3=NN=2)C(\C)=N\OCCO)=C2)C2=C1 IYSRDIPKAXCGSE-XSZJBBQGSA-N 0.000 description 1
- XOSWEUYBKJZODE-CGKHLXHRSA-N 2-[(e)-1-[3-[3-[(3s)-3-(dimethylamino)pyrrolidin-1-yl]quinolin-6-yl]sulfanyl-[1,2,4]triazolo[4,3-a]pyridin-6-yl]ethylideneamino]oxyethanol Chemical compound C1[C@@H](N(C)C)CCN1C1=CN=C(C=CC(SC=2N3C=C(C=CC3=NN=2)C(\C)=N\OCCO)=C2)C2=C1 XOSWEUYBKJZODE-CGKHLXHRSA-N 0.000 description 1
- JZIKZJCBYAYGEA-UHFFFAOYSA-N 2-[4-[3-(3-morpholin-4-ylquinolin-6-yl)sulfanyl-[1,2,4]triazolo[4,3-a]pyridin-6-yl]pyrazol-1-yl]ethanol Chemical compound C1=NN(CCO)C=C1C1=CN2C(SC=3C=C4C=C(C=NC4=CC=3)N3CCOCC3)=NN=C2C=C1 JZIKZJCBYAYGEA-UHFFFAOYSA-N 0.000 description 1
- RECGTOTUFYGHJY-UHFFFAOYSA-N 2-[4-[6-[[6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]quinolin-3-yl]-1,4-diazepan-1-yl]ethanol Chemical compound C1=NN(C)C=C1C1=CN2C(SC=3C=C4C=C(C=NC4=CC=3)N3CCN(CCO)CCC3)=NN=C2C=C1 RECGTOTUFYGHJY-UHFFFAOYSA-N 0.000 description 1
- QXMNTGNVLMNHEO-UHFFFAOYSA-N 2-[6-[[6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]quinolin-3-yl]-8-oxa-2-azaspiro[4.5]decane Chemical compound C1=NN(C)C=C1C1=CN2C(SC=3C=C4C=C(C=NC4=CC=3)N3CC4(CC3)CCOCC4)=NN=C2C=C1 QXMNTGNVLMNHEO-UHFFFAOYSA-N 0.000 description 1
- WHWAOQDLIBFTNE-UHFFFAOYSA-N 2-[6-[[8-fluoro-6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]quinolin-3-yl]-8-oxa-2-azaspiro[4.5]decane Chemical compound C1=NN(C)C=C1C1=CN2C(SC=3C=C4C=C(C=NC4=CC=3)N3CC4(CC3)CCOCC4)=NN=C2C(F)=C1 WHWAOQDLIBFTNE-UHFFFAOYSA-N 0.000 description 1
- NOIXNOMHHWGUTG-UHFFFAOYSA-N 2-[[4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC(F)(F)F)C=C1C1=CC=NC=C1 NOIXNOMHHWGUTG-UHFFFAOYSA-N 0.000 description 1
- KSZWVRDXHXOEKN-UHFFFAOYSA-N 2-methyl-4-[6-[[6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]quinolin-3-yl]morpholine Chemical compound C1COC(C)CN1C1=CN=C(C=CC(SC=2N3C=C(C=CC3=NN=2)C2=CN(C)N=C2)=C2)C2=C1 KSZWVRDXHXOEKN-UHFFFAOYSA-N 0.000 description 1
- KCSVVCQNVWNDNF-UHFFFAOYSA-N 3-(1,4-diazepan-1-yl)-6-[[6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]quinoline Chemical compound C1=NN(C)C=C1C1=CN2C(SC=3C=C4C=C(C=NC4=CC=3)N3CCNCCC3)=NN=C2C=C1 KCSVVCQNVWNDNF-UHFFFAOYSA-N 0.000 description 1
- OHQMOXPQJBEGOZ-UHFFFAOYSA-N 3-(4,4-difluoropiperidin-1-yl)-6-[[6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]quinoline Chemical compound C1=NN(C)C=C1C1=CN2C(SC=3C=C4C=C(C=NC4=CC=3)N3CCC(F)(F)CC3)=NN=C2C=C1 OHQMOXPQJBEGOZ-UHFFFAOYSA-N 0.000 description 1
- IABXEOYJCXGIMD-UHFFFAOYSA-N 3-(4,4-difluoropiperidin-1-yl)-6-[[8-fluoro-6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]quinoline Chemical compound C1=NN(C)C=C1C1=CN2C(SC=3C=C4C=C(C=NC4=CC=3)N3CCC(F)(F)CC3)=NN=C2C(F)=C1 IABXEOYJCXGIMD-UHFFFAOYSA-N 0.000 description 1
- XHWNFTZGGRJFLV-UHFFFAOYSA-N 3-(4-cyclohexylpiperazin-1-yl)-6-[[6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]quinoline Chemical compound C1=NN(C)C=C1C1=CN2C(SC=3C=C4C=C(C=NC4=CC=3)N3CCN(CC3)C3CCCCC3)=NN=C2C=C1 XHWNFTZGGRJFLV-UHFFFAOYSA-N 0.000 description 1
- KODNKVYGOJLHDP-UHFFFAOYSA-N 3-(4-methyl-1,4-diazepan-1-yl)-6-[[6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]quinoline Chemical compound C1CN(C)CCCN1C1=CN=C(C=CC(SC=2N3C=C(C=CC3=NN=2)C2=CN(C)N=C2)=C2)C2=C1 KODNKVYGOJLHDP-UHFFFAOYSA-N 0.000 description 1
- MAEFTXPFQHILHT-UHFFFAOYSA-N 3-[(4-methylpiperazin-1-yl)methyl]-6-[[6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]quinoline Chemical compound C1CN(C)CCN1CC1=CN=C(C=CC(SC=2N3C=C(C=CC3=NN=2)C2=CN(C)N=C2)=C2)C2=C1 MAEFTXPFQHILHT-UHFFFAOYSA-N 0.000 description 1
- MDINHUDZVSNDEL-UHFFFAOYSA-N 3-methyl-4-[6-[[6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]quinolin-3-yl]morpholine Chemical compound CC1COCCN1C1=CN=C(C=CC(SC=2N3C=C(C=CC3=NN=2)C2=CN(C)N=C2)=C2)C2=C1 MDINHUDZVSNDEL-UHFFFAOYSA-N 0.000 description 1
- PYICCQVWUOKFSY-UHFFFAOYSA-N 4-[6-[[6-(1h-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]quinolin-3-yl]morpholine Chemical compound C1COCCN1C1=CN=C(C=CC(SC=2N3C=C(C=CC3=NN=2)C2=CNN=C2)=C2)C2=C1 PYICCQVWUOKFSY-UHFFFAOYSA-N 0.000 description 1
- CKHSZGOIKJWYLP-UHFFFAOYSA-N 4-[6-[[8-fluoro-6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]quinolin-3-yl]-2,6-dimethylmorpholine Chemical compound C1C(C)OC(C)CN1C1=CN=C(C=CC(SC=2N3C=C(C=C(F)C3=NN=2)C2=CN(C)N=C2)=C2)C2=C1 CKHSZGOIKJWYLP-UHFFFAOYSA-N 0.000 description 1
- NLRBOMANTTVJTI-UHFFFAOYSA-N 4-[6-[[8-fluoro-6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]quinolin-3-yl]-2-methylmorpholine Chemical compound C1COC(C)CN1C1=CN=C(C=CC(SC=2N3C=C(C=C(F)C3=NN=2)C2=CN(C)N=C2)=C2)C2=C1 NLRBOMANTTVJTI-UHFFFAOYSA-N 0.000 description 1
- KUYMCRLOLWIWOI-UHFFFAOYSA-N 4-[6-[[8-fluoro-6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]quinolin-3-yl]-3-methylmorpholine Chemical compound CC1COCCN1C1=CN=C(C=CC(SC=2N3C=C(C=C(F)C3=NN=2)C2=CN(C)N=C2)=C2)C2=C1 KUYMCRLOLWIWOI-UHFFFAOYSA-N 0.000 description 1
- XVVKQPOCKFTKCR-UHFFFAOYSA-N 4-[6-[[8-fluoro-6-(1h-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]quinolin-3-yl]morpholine Chemical compound N=1N=C2C(F)=CC(C3=CNN=C3)=CN2C=1SC(C=C1C=2)=CC=C1N=CC=2N1CCOCC1 XVVKQPOCKFTKCR-UHFFFAOYSA-N 0.000 description 1
- ARFVFRRCPKPXGP-UHFFFAOYSA-N 4-[[6-[[6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]quinolin-3-yl]methyl]morpholine Chemical compound C1=NN(C)C=C1C1=CN2C(SC=3C=C4C=C(CN5CCOCC5)C=NC4=CC=3)=NN=C2C=C1 ARFVFRRCPKPXGP-UHFFFAOYSA-N 0.000 description 1
- GNCNEAGBGRHTAT-UHFFFAOYSA-N 6-[6-[[6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]quinolin-3-yl]-2-oxa-6-azaspiro[3.3]heptane Chemical compound C1=NN(C)C=C1C1=CN2C(SC=3C=C4C=C(C=NC4=CC=3)N3CC4(COC4)C3)=NN=C2C=C1 GNCNEAGBGRHTAT-UHFFFAOYSA-N 0.000 description 1
- WAZOXVCSFBYHOO-UHFFFAOYSA-N 6-[[6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]-3-(4-phenylpiperazin-1-yl)quinoline Chemical compound C1=NN(C)C=C1C1=CN2C(SC=3C=C4C=C(C=NC4=CC=3)N3CCN(CC3)C=3C=CC=CC=3)=NN=C2C=C1 WAZOXVCSFBYHOO-UHFFFAOYSA-N 0.000 description 1
- QTDCAXYCFZXWPG-UHFFFAOYSA-N 6-[[6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]-3-(4-piperidin-1-ylpiperidin-1-yl)quinoline Chemical compound C1=NN(C)C=C1C1=CN2C(SC=3C=C4C=C(C=NC4=CC=3)N3CCC(CC3)N3CCCCC3)=NN=C2C=C1 QTDCAXYCFZXWPG-UHFFFAOYSA-N 0.000 description 1
- TWVWCIKZBQUKNQ-UHFFFAOYSA-N 6-[[6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]-3-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]quinoline Chemical compound C1=NN(C)C=C1C1=CN2C(SC=3C=C4C=C(C=NC4=CC=3)N3CCN(CC(F)(F)F)CC3)=NN=C2C=C1 TWVWCIKZBQUKNQ-UHFFFAOYSA-N 0.000 description 1
- LQLJOSBZSDCEPQ-UHFFFAOYSA-N 6-[[8-fluoro-6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]-3-(4-piperidin-1-ylpiperidin-1-yl)quinoline Chemical compound C1=NN(C)C=C1C1=CN2C(SC=3C=C4C=C(C=NC4=CC=3)N3CCC(CC3)N3CCCCC3)=NN=C2C(F)=C1 LQLJOSBZSDCEPQ-UHFFFAOYSA-N 0.000 description 1
- IFBRUUOIKYNFQU-UHFFFAOYSA-N 6-[[8-fluoro-6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]-3-(4-pyrrolidin-1-ylpiperidin-1-yl)quinoline Chemical compound C1=NN(C)C=C1C1=CN2C(SC=3C=C4C=C(C=NC4=CC=3)N3CCC(CC3)N3CCCC3)=NN=C2C(F)=C1 IFBRUUOIKYNFQU-UHFFFAOYSA-N 0.000 description 1
- CIPJSPNNLSDSSM-HNNXBMFYSA-N 6-[[8-fluoro-6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]-3-[(2s)-2-methylpiperazin-1-yl]quinoline Chemical compound C[C@H]1CNCCN1C1=CN=C(C=CC(SC=2N3C=C(C=C(F)C3=NN=2)C2=CN(C)N=C2)=C2)C2=C1 CIPJSPNNLSDSSM-HNNXBMFYSA-N 0.000 description 1
- IMTTXYPMOVLULF-UHFFFAOYSA-N 6-[[8-fluoro-6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]-n-(1-methylpiperidin-4-yl)quinolin-3-amine Chemical compound C1CN(C)CCC1NC1=CN=C(C=CC(SC=2N3C=C(C=C(F)C3=NN=2)C2=CN(C)N=C2)=C2)C2=C1 IMTTXYPMOVLULF-UHFFFAOYSA-N 0.000 description 1
- IVGLGVJCVDBHBJ-UHFFFAOYSA-N CC=NOCCO Chemical compound CC=NOCCO IVGLGVJCVDBHBJ-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- ZBAAKUHERHHMAH-UHFFFAOYSA-N n-(1-methylpiperidin-4-yl)-6-[[6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulfanyl]quinolin-3-amine Chemical compound C1CN(C)CCC1NC1=CN=C(C=CC(SC=2N3C=C(C=CC3=NN=2)C2=CN(C)N=C2)=C2)C2=C1 ZBAAKUHERHHMAH-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2011/079695 | 2011-09-15 | ||
| CN2011079695 | 2011-09-15 | ||
| CN2012079055 | 2012-07-23 | ||
| CNPCT/CN2012/079055 | 2012-07-23 | ||
| PCT/IB2012/054775 WO2013038362A1 (en) | 2011-09-15 | 2012-09-13 | 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014526499A JP2014526499A (ja) | 2014-10-06 |
| JP2014526499A5 true JP2014526499A5 (https=) | 2015-11-05 |
| JP5957526B2 JP5957526B2 (ja) | 2016-07-27 |
Family
ID=46981017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014530361A Expired - Fee Related JP5957526B2 (ja) | 2011-09-15 | 2012-09-13 | チロシンキナーゼとしての６−置換３−（キノリン−６−イルチオ）−［１，２，４］トリアゾロ［４，３−ａ］ピラジン |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9062045B2 (https=) |
| EP (1) | EP2755976B1 (https=) |
| JP (1) | JP5957526B2 (https=) |
| KR (1) | KR20140077916A (https=) |
| AR (1) | AR087868A1 (https=) |
| AU (1) | AU2012310168B2 (https=) |
| BR (1) | BR112014006223A8 (https=) |
| CA (1) | CA2848809A1 (https=) |
| EA (1) | EA026655B1 (https=) |
| ES (1) | ES2691650T3 (https=) |
| MX (1) | MX339302B (https=) |
| TW (1) | TW201319067A (https=) |
| UY (1) | UY34329A (https=) |
| WO (1) | WO2013038362A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014262326B2 (en) * | 2013-05-10 | 2018-03-22 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | [1,2,4] triazol [4,3-a] pyridine derivate, preparation method therefor or medical application thereof |
| EP3013825B1 (en) | 2013-06-24 | 2019-08-07 | Amgen Inc. | Method for the preparation of (1,2,4)-triazolo(4,3-a)pyridines |
| GB201321742D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| KR102516745B1 (ko) * | 2014-08-01 | 2023-03-31 | 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 | Ｃ-Ｍｅｔ 억제제의 결정질 유리 염기 또는 이의 결정질 산 염, 및 이들의 제조방법 및 용도 |
| WO2017049711A1 (zh) | 2015-09-24 | 2017-03-30 | 上海海聚生物科技有限公司 | 喹啉类衍生物、其药物组合物、制备方法及应用 |
| CN106883250B (zh) * | 2015-12-15 | 2021-05-18 | 江苏豪森药业集团有限公司 | C-Met酪氨酸激酶抑制剂的制备方法 |
| MX2020011275A (es) | 2018-04-25 | 2020-11-13 | Bayer Ag | Novedosos compuestos de heteroaril-triazol y hetroaril[-]tetrazol como plaguicidas. |
| JP7689109B2 (ja) | 2019-07-23 | 2025-06-05 | バイエル・アクチエンゲゼルシヤフト | 農薬としての新規ヘテロアリール－トリアゾール化合物 |
| US20220274947A1 (en) | 2019-07-23 | 2022-09-01 | Bayer Aktiengesellschaft | Novel heteroaryl-triazole compounds as pesticides |
| CN111440174B (zh) * | 2020-04-02 | 2021-07-09 | 广州医科大学 | 一种吡啶酰胺类化合物及其制备方法与应用 |
Family Cites Families (193)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1219606A (en) | 1968-07-15 | 1971-01-20 | Rech S Et D Applic Scient Soge | Quinuclidinol derivatives and preparation thereof |
| GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
| US4358453A (en) | 1982-01-08 | 1982-11-09 | Schering Corporation | 1,2,4-Triazolo[4,3-a]pyridines |
| EP0100172B1 (en) | 1982-07-23 | 1987-08-12 | Imperial Chemical Industries Plc | Amide derivatives |
| GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
| FR2601952B1 (fr) | 1986-07-23 | 1988-11-25 | Carpibem | Nouveaux derives amino alkyl thio de triazolopyridine ou triazoloquinoline, leurs procedes de preparation, medicaments les contenant, utiles notamment comme antalgiques |
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| GB8916480D0 (en) | 1989-07-19 | 1989-09-06 | Glaxo Group Ltd | Chemical process |
| US5010099A (en) | 1989-08-11 | 1991-04-23 | Harbor Branch Oceanographic Institution, Inc. | Discodermolide compounds, compositions containing same and method of preparation and use |
| GB8923590D0 (en) | 1989-10-19 | 1989-12-06 | Pfizer Ltd | Antimuscarinic bronchodilators |
| US5395855A (en) | 1990-05-07 | 1995-03-07 | Ciba-Geigy Corporation | Hydrazones |
| PT100441A (pt) | 1991-05-02 | 1993-09-30 | Smithkline Beecham Corp | Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso |
| US5451700A (en) | 1991-06-11 | 1995-09-19 | Ciba-Geigy Corporation | Amidino compounds, their manufacture and methods of treatment |
| NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| EP0636026B1 (en) | 1992-04-02 | 2001-12-05 | Smithkline Beecham Corporation | Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor |
| JP3192424B2 (ja) | 1992-04-02 | 2001-07-30 | スミスクライン・ビーチャム・コーポレイション | アレルギーまたは炎症疾患の治療用化合物 |
| HU225869B1 (en) | 1992-04-02 | 2007-11-28 | Smithkline Beecham Corp | Compounds with antiallergic and antiinflammatory activity and pharmaceutical compns. contg. them |
| TW225528B (https=) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| BR9207175A (pt) | 1992-10-28 | 1995-12-12 | Genentech Inc | Composição contendo antagonista de fator de crescimento de célula endotelial vascular sequência aminoácida de anticorpo monoclonal polipeptídeo e método de tratamento de tumor em mamífero |
| GB9301000D0 (en) | 1993-01-20 | 1993-03-10 | Glaxo Group Ltd | Chemical compounds |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| DE4326758A1 (de) | 1993-08-10 | 1995-02-16 | Basf Ag | [1,3,4]Triazolo[1,5-a]pyridine |
| DE4329296A1 (de) | 1993-08-31 | 1995-03-02 | Basf Ag | Azofarbstoffe mit einer Diazokomponente aus der Anilinreihe und Kupplungskomponente aus der Triazolopyridinreihe |
| GB9414193D0 (en) | 1994-07-14 | 1994-08-31 | Glaxo Group Ltd | Compounds |
| GB9414208D0 (en) | 1994-07-14 | 1994-08-31 | Glaxo Group Ltd | Compounds |
| MX9707453A (es) | 1995-03-30 | 1997-12-31 | Pfizer | Derivados de quinazolina. |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| MX9800215A (es) | 1995-07-06 | 1998-03-31 | Novartis Ag | Pirrolopirimidas y procesos para su preparacion. |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| HU228446B1 (en) | 1996-04-12 | 2013-03-28 | Warner Lambert Co | Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof |
| EP0907642B1 (en) | 1996-06-24 | 2005-11-02 | Pfizer Inc. | Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases |
| EP0923583A1 (de) | 1996-08-30 | 1999-06-23 | Novartis AG | Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens |
| DE69724269T2 (de) | 1996-09-06 | 2004-06-09 | Obducat Ab | Verfahren für das anisotrope ätzen von strukturen in leitende materialien |
| DE19638745C2 (de) | 1996-09-11 | 2001-05-10 | Schering Ag | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
| CA2265630A1 (en) | 1996-09-13 | 1998-03-19 | Gerald Mcmahon | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
| EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
| GB9622386D0 (en) | 1996-10-28 | 1997-01-08 | Sandoz Ltd | Organic compounds |
| DK1367057T3 (da) | 1996-11-18 | 2009-01-19 | Biotechnolog Forschung Gmbh | Epothiloner E og F |
| US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
| TW528755B (en) | 1996-12-24 | 2003-04-21 | Glaxo Group Ltd | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives |
| CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| US6166037A (en) | 1997-08-28 | 2000-12-26 | Merck & Co., Inc. | Pyrrolidine and piperidine modulators of chemokine receptor activity |
| AU9281298A (en) | 1997-10-01 | 1999-04-23 | Kyowa Hakko Kogyo Co. Ltd. | Benzodioxole derivatives |
| GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
| GB9723589D0 (en) | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
| GB9723590D0 (en) | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
| GB9723566D0 (en) | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
| YU44900A (sh) | 1998-01-31 | 2003-01-31 | Glaxo Group Limited | Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola |
| PE20000270A1 (es) | 1998-02-14 | 2000-05-20 | Glaxo Group Ltd | Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol |
| US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
| DE69927790T2 (de) | 1998-02-25 | 2006-07-20 | Sloan-Kettering Institute For Cancer Research | Synthese von epothilonen, ihren zwischenprodukten und analogen verbindungen |
| AU750462B2 (en) | 1998-06-23 | 2002-07-18 | Glaxo Group Limited | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives |
| GB9813535D0 (en) | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
| GB9813565D0 (en) | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
| GB9813540D0 (en) | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
| KR100563395B1 (ko) | 1998-06-30 | 2006-03-23 | 다우 글로벌 테크놀로지스 인크. | 중합체 폴리올 및 이의 제조방법 |
| US6303625B1 (en) | 1998-07-27 | 2001-10-16 | Ortho-Mcneil Pharmaceutical, Inc. | Triazolopyridines for the treatment of thrombosis disorders |
| ATE459616T1 (de) | 1998-08-11 | 2010-03-15 | Novartis Ag | Isochinoline derivate mit angiogenesis-hemmender wirkung |
| AU5879299A (en) | 1998-10-16 | 2000-05-08 | Monaghan, Sandra Marina | Adenine derivatives |
| UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
| GB9824579D0 (en) | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
| NZ511722A (en) | 1998-11-20 | 2004-05-28 | Kosan Biosciences Inc | Recombinant methods and materials for producing epothilone and epothilone derivatives |
| WO2000037502A2 (en) | 1998-12-22 | 2000-06-29 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists and uses thereof |
| WO2000059509A1 (en) | 1999-03-30 | 2000-10-12 | Novartis Ag | Phthalazine derivatives for treating inflammatory diseases |
| GB9913083D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
| CA2371583C (en) | 1999-05-04 | 2005-09-13 | Schering Corporation | Piperazine derivatives useful as ccr5 antagonists |
| HK1039330B (en) | 1999-05-04 | 2005-12-09 | Schering Corporation | Piperidine derivatives useful as ccr5 antagonists |
| YU25500A (sh) | 1999-05-11 | 2003-08-29 | Pfizer Products Inc. | Postupak za sintezu analoga nukleozida |
| GB9913932D0 (en) | 1999-06-15 | 1999-08-18 | Pfizer Ltd | Purine derivatives |
| US6322771B1 (en) | 1999-06-18 | 2001-11-27 | University Of Virginia Patent Foundation | Induction of pharmacological stress with adenosine receptor agonists |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| US6333335B1 (en) | 1999-07-23 | 2001-12-25 | Merck & Co., Inc. | Phenyl-protein transferase inhibitors |
| EP1212089B1 (en) | 1999-08-21 | 2006-03-22 | ALTANA Pharma AG | Synergistic combination of roflumilast and salmeterol |
| CO5180581A1 (es) | 1999-09-30 | 2002-07-30 | Pfizer Prod Inc | Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia |
| GB9924363D0 (en) | 1999-10-14 | 1999-12-15 | Pfizer Central Res | Purine derivatives |
| GB9924361D0 (en) | 1999-10-14 | 1999-12-15 | Pfizer Ltd | Purine derivatives |
| GB0003960D0 (en) | 2000-02-18 | 2000-04-12 | Pfizer Ltd | Purine derivatives |
| TWI227240B (en) | 2000-06-06 | 2005-02-01 | Pfizer | 2-aminocarbonyl-9H-purine derivatives |
| CZ294251B6 (cs) | 2000-06-27 | 2004-11-10 | Laboratorios S. A. L. V. A. T., S. A. | Karbamáty a jejich použití pro výrobu farmaceutického prostředku |
| GB0015727D0 (en) | 2000-06-27 | 2000-08-16 | Pfizer Ltd | Purine derivatives |
| GB0015876D0 (en) | 2000-06-28 | 2000-08-23 | Novartis Ag | Organic compounds |
| DE10038639A1 (de) | 2000-07-28 | 2002-02-21 | Schering Ag | Nichtsteroidale Entzündungshemmer |
| DE10038019A1 (de) | 2000-08-04 | 2002-02-14 | Bayer Ag | Substituierte Triazolopyrid(az)ine |
| WO2002012266A1 (en) | 2000-08-05 | 2002-02-14 | Glaxo Group Limited | 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| GB0022695D0 (en) | 2000-09-15 | 2000-11-01 | Pfizer Ltd | Purine Derivatives |
| GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
| JP4445704B2 (ja) | 2000-12-22 | 2010-04-07 | アルミラル・ソシエダッド・アノニマ | キヌクリジンカルバメート誘導体およびｍ３アンダゴニストとしてのそれらの使用 |
| IL156558A0 (en) | 2000-12-28 | 2004-01-04 | Almirall Prodesfarma Ag | Novel quinuclidine derivatives and medicinal compositions containing the same |
| EP1241176A1 (en) | 2001-03-16 | 2002-09-18 | Pfizer Products Inc. | Purine derivatives for the treatment of ischemia |
| PT1383786E (pt) | 2001-04-30 | 2008-12-30 | Glaxo Group Ltd | Derivados anti-inflamatórios de éster 17.beta-carbotioato de androstano com um grupo éster ciclíco na posição 17.alfa |
| AR035885A1 (es) | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
| CZ20033126A3 (cs) | 2001-05-25 | 2004-09-15 | Pfizer Inc. | Kombinace agonistu adenosin A2a receptoru a anticholinergického činidla pro ošetřování obstruktivních nemocí dýchacích cest |
| US20040248867A1 (en) | 2001-06-12 | 2004-12-09 | Keith Biggadike | Novel anti-inflammatory 17.alpha.-heterocyclic-esters of 17.beta.carbothioate androstane derivatives |
| EP2319919B1 (en) | 2001-06-21 | 2015-08-12 | BASF Enzymes LLC | Nitrilases |
| GB0119249D0 (en) | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
| JP2005512974A (ja) | 2001-10-17 | 2005-05-12 | ユ セ ベ ソシエテ アノニム | キヌクリジン誘導体、その調製方法、及びｍ２及び／又はｍ３ムスカリン受容体阻害剤としてのその使用 |
| GB0125259D0 (en) | 2001-10-20 | 2001-12-12 | Glaxo Group Ltd | Novel compounds |
| AR037517A1 (es) | 2001-11-05 | 2004-11-17 | Novartis Ag | Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria |
| WO2003048181A1 (en) | 2001-12-01 | 2003-06-12 | Glaxo Group Limited | 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents |
| EP1461336B1 (en) | 2001-12-20 | 2013-05-22 | CHIESI FARMACEUTICI S.p.A. | 1-alkyl-1-azoniabicyclo (2.2.2) octane carbamate derivatives and their use as muscarinic receptor antagonists |
| WO2003072592A1 (en) | 2002-01-15 | 2003-09-04 | Glaxo Group Limited | 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents |
| WO2003062259A2 (en) | 2002-01-21 | 2003-07-31 | Glaxo Group Limited | Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents |
| GB0202216D0 (en) | 2002-01-31 | 2002-03-20 | Glaxo Group Ltd | Novel compounds |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| CA2477764A1 (en) | 2002-03-26 | 2003-10-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| UA80120C2 (en) | 2002-03-26 | 2007-08-27 | Boehringer Ingelheim Pharma | Glucocorticoid mimetics, pharmaceutical composition based thereon |
| AU2003234716A1 (en) | 2002-04-10 | 2003-10-27 | Joel M. Linden | Use of a2a adenosine receptor agonists for the treatment of inflammatory diseases |
| ES2206021B1 (es) | 2002-04-16 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de pirrolidinio. |
| ES2201907B1 (es) | 2002-05-29 | 2005-06-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de indolilpiperidina como potentes agentes antihistaminicos y antialergicos. |
| DE10224888A1 (de) | 2002-06-05 | 2003-12-24 | Merck Patent Gmbh | Pyridazinderivate |
| US7074806B2 (en) | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| DE10225574A1 (de) | 2002-06-10 | 2003-12-18 | Merck Patent Gmbh | Aryloxime |
| DE10227269A1 (de) | 2002-06-19 | 2004-01-08 | Merck Patent Gmbh | Thiazolderivate |
| EP1517895B1 (en) | 2002-06-25 | 2007-03-14 | Merck Frosst Canada Ltd. | 8-(biaryl) quinoline pde4 inhibitors |
| EP1519922A1 (en) | 2002-07-02 | 2005-04-06 | Merck Frosst Canada & Co. | Di-aryl-substituted ethane pyridone pde4 inhibitors |
| ES2204295B1 (es) | 2002-07-02 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de quinuclidina-amida. |
| SI1521733T1 (sl) | 2002-07-08 | 2014-10-30 | Pfizer Products Inc. | Modulatorji glukokortikoidnega receptorja |
| PE20050130A1 (es) | 2002-08-09 | 2005-03-29 | Novartis Ag | Compuestos organicos |
| WO2004018450A1 (en) | 2002-08-10 | 2004-03-04 | Altana Pharma Ag | Piperidine-n-oxide-derivatives |
| CA2494613C (en) | 2002-08-10 | 2011-06-28 | Altana Pharma Ag | Pyrrolidinedione substituted piperidine-phthalazones as pde4 inhibitors |
| AU2003255376A1 (en) | 2002-08-10 | 2004-03-11 | Altana Pharma Ag | Piperidine-derivatives as pde4 inhibitors |
| WO2004018451A1 (en) | 2002-08-10 | 2004-03-04 | Altana Pharma Ag | Pyridazinone-derivatives as pde4 inhibitors |
| EP1581533A2 (en) | 2002-08-17 | 2005-10-05 | ALTANA Pharma AG | Novel benzonaphthyridines |
| AU2003253408A1 (en) | 2002-08-17 | 2004-03-11 | Nycomed Gmbh | Novel phenanthridines |
| SE0202483D0 (sv) | 2002-08-21 | 2002-08-21 | Astrazeneca Ab | Chemical compounds |
| JP2006501236A (ja) | 2002-08-23 | 2006-01-12 | ランバクシー ラボラトリーズ リミテッド | ムスカリン性レセプター拮抗薬としてのフルオロおよびスルホニルアミノ含有３，６−二置換アザビシクロ（３．１．０）ヘキサン誘導体 |
| CA2495827C (en) | 2002-08-29 | 2012-05-08 | Altana Pharma Ag | 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors |
| ES2281658T3 (es) | 2002-08-29 | 2007-10-01 | Nycomed Gmbh | 3-hidroxi-6-fenilfenantridinas como inhibidores de pde-4. |
| MXPA05002123A (es) | 2002-08-30 | 2005-06-06 | Pfizer Prod Inc | Nuevos procedimientos e intermedios para preparar triazolo-piridinas. |
| JP2006096662A (ja) | 2002-09-18 | 2006-04-13 | Sumitomo Pharmaceut Co Ltd | 新規６−置換ウラシル誘導体及びアレルギー性疾患の治療剤 |
| EP1541574A4 (en) | 2002-09-18 | 2007-06-20 | Ono Pharmaceutical Co | TRIAZASPIRO DERIVATIVES 5.5 | UNDECANS AND DRUGS CONTAINING THEM AS AN ACTIVE INGREDIENT |
| JP2004107299A (ja) | 2002-09-20 | 2004-04-08 | Japan Energy Corp | 新規１−置換ウラシル誘導体及びアレルギー性疾患の治療剤 |
| DE10246374A1 (de) | 2002-10-04 | 2004-04-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| EA010408B1 (ru) | 2002-10-23 | 2008-08-29 | Гленмарк Фармасьютикалс Лтд. | Трициклические соединения для лечения воспалительных и аллергических нарушений, способы их приготовления и содержащие их фармацевтические составы |
| GB0225535D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| DE10253220A1 (de) | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Dihydroxy-Methyl-Phenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| DE10253282A1 (de) | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung |
| DE10253426B4 (de) | 2002-11-15 | 2005-09-22 | Elbion Ag | Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung |
| US7915293B2 (en) | 2003-05-30 | 2011-03-29 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
| US7538120B2 (en) | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
| US20050256309A1 (en) | 2004-05-12 | 2005-11-17 | Altenbach Robert J | Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands |
| US7205316B2 (en) | 2004-05-12 | 2007-04-17 | Abbott Laboratories | Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands |
| BRPI0514391A (pt) | 2004-08-18 | 2008-06-10 | Pharmacia & Upjohn Co Llc | compostos de triazolopiridina para o tratamento de inflamação |
| ATE479687T1 (de) | 2004-10-15 | 2010-09-15 | Takeda Pharmaceutical | Kinaseinhibitoren |
| US7456289B2 (en) | 2004-12-31 | 2008-11-25 | National Health Research Institutes | Anti-tumor compounds |
| US7579348B2 (en) | 2005-02-25 | 2009-08-25 | Pgxhealth, Llc | Derivatives of 8-substituted xanthines |
| US7572807B2 (en) | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
| US7632837B2 (en) | 2005-06-17 | 2009-12-15 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid-1 receptor modulators |
| HUE030390T2 (en) | 2005-12-21 | 2017-05-29 | Janssen Pharmaceutica Nv | Triazolopyridazines as tyrosine kinase modulators |
| EP2004693B1 (en) | 2006-03-30 | 2012-06-06 | Novartis AG | Compositions and methods of use for antibodies of c-met |
| NL2000613C2 (nl) | 2006-05-11 | 2007-11-20 | Pfizer Prod Inc | Triazoolpyrazinederivaten. |
| JP2009538899A (ja) | 2006-05-30 | 2009-11-12 | ファイザー・プロダクツ・インク | トリアゾロピリダジン誘導体 |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| PE20080403A1 (es) | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
| CA2667453A1 (en) | 2006-10-23 | 2008-05-02 | Sgx Pharmaceuticals, Inc. | Triazolo-pyridazine protein kinase modulators |
| AU2007309149C1 (en) * | 2006-10-23 | 2013-04-04 | Sgx Pharmaceuticals, Inc. | Bicyclic triazoles as protein kinase modulators |
| ME02372B (me) | 2006-11-22 | 2016-06-20 | Incyte Holdings Corp | Imidazotriazini i imidazopiramidini kao inhibitori kinaze |
| EP2170894A1 (en) | 2007-06-21 | 2010-04-07 | Janssen Pharmaceutica N.V. | Polymorphic and hydrate forms, salts and process for preparing 6-{difluoro[6-(1-methyl-1h-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}quinoline |
| PA8792501A1 (es) | 2007-08-09 | 2009-04-23 | Sanofi Aventis | Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met. |
| BRPI0816064B8 (pt) | 2007-08-29 | 2021-05-25 | Methylgene Inc | composto inibidor da atividade de proteína tirosina quinase, seu uso, e composição farmacêutica |
| US8119658B2 (en) | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| US20110039856A1 (en) | 2007-11-29 | 2011-02-17 | Pfizer Inc. | Polymorphs of a c-met/hgfr inhibitor |
| US8450343B2 (en) | 2007-12-06 | 2013-05-28 | Xianhai Huang | Gamma secretase modulators |
| PE20091468A1 (es) | 2008-02-28 | 2009-10-22 | Novartis Ag | DERIVADOS DE 3-METIL-IMIDAZO-[1,2-b]-PIRIDAZINA |
| WO2009143211A2 (en) | 2008-05-21 | 2009-11-26 | Incyte Corporation | Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same |
| PE20110560A1 (es) | 2008-07-18 | 2011-08-29 | Sanofi Aventis | NUEVOS DERIVADOS DE TRIAZOLO[4,3-a]PIRIDINA, SU PROCEDIMIENTO DE PREPARACION, SU APLICACION COMO MEDICAMENTOS, COMPOSICIONES FARMACEUTICAS Y NUEVA UTILIZACION PARTICULARMENTE COMO INHIBIDORES DE MET |
| UY32049A (es) | 2008-08-14 | 2010-03-26 | Takeda Pharmaceutical | Inhibidores de cmet |
| FR2941950B1 (fr) | 2009-02-06 | 2011-04-01 | Sanofi Aventis | Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met. |
| FR2941949B1 (fr) | 2009-02-06 | 2011-04-01 | Sanofi Aventis | Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met. |
| FR2941952B1 (fr) | 2009-02-06 | 2011-04-01 | Sanofi Aventis | Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met. |
| FR2941951B1 (fr) | 2009-02-06 | 2011-04-01 | Sanofi Aventis | Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met. |
| CN102439008B (zh) | 2009-05-12 | 2015-04-29 | 杨森制药有限公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途 |
| CN102448969A (zh) | 2009-05-28 | 2012-05-09 | 沃泰克斯药物股份有限公司 | C-met蛋白激酶抑制剂 |
| US8952034B2 (en) | 2009-07-27 | 2015-02-10 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| UA107360C2 (en) | 2009-08-05 | 2014-12-25 | Biogen Idec Inc | Bicyclic aryl sphingosine 1-phosphate analogs |
| US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
| JP5781510B2 (ja) | 2009-08-12 | 2015-09-24 | ノバルティス アーゲー | ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用 |
| JP5775871B2 (ja) | 2009-08-20 | 2015-09-09 | ノバルティス アーゲー | ヘテロ環式オキシム化合物 |
| US9180127B2 (en) | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
| BR112012020273A8 (pt) | 2010-02-11 | 2017-12-26 | Univ Vanderbilt | compostos de pirazolopiridina, pirazolopirazina, pirazolopirimidina, pirazolotiofeno e pirazolotiazol como pontencializadores alostéricos de mglur4, composições e métodos de tratamento de disfunção neurológica |
| US8299117B2 (en) | 2010-06-16 | 2012-10-30 | Metabolex Inc. | GPR120 receptor agonists and uses thereof |
| EP2425830A1 (en) | 2010-09-03 | 2012-03-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Synergistic drug combination for the treatment of cancer |
| EP2621483A1 (en) | 2010-09-27 | 2013-08-07 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases |
| US20120100157A1 (en) | 2010-10-11 | 2012-04-26 | Van Andel Research Institute | Biomarker and Method for Predicting Sensitivity to MET Inhibitors |
| WO2012107500A1 (en) * | 2011-02-10 | 2012-08-16 | Novartis Ag | [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase |
-
2012
- 2012-09-13 EA EA201490630A patent/EA026655B1/ru not_active IP Right Cessation
- 2012-09-13 BR BR112014006223A patent/BR112014006223A8/pt not_active IP Right Cessation
- 2012-09-13 EP EP12769172.3A patent/EP2755976B1/en not_active Not-in-force
- 2012-09-13 UY UY0001034329A patent/UY34329A/es not_active Application Discontinuation
- 2012-09-13 US US13/613,291 patent/US9062045B2/en active Active
- 2012-09-13 ES ES12769172.3T patent/ES2691650T3/es active Active
- 2012-09-13 CA CA2848809A patent/CA2848809A1/en not_active Abandoned
- 2012-09-13 MX MX2014003194A patent/MX339302B/es active IP Right Grant
- 2012-09-13 AU AU2012310168A patent/AU2012310168B2/en not_active Ceased
- 2012-09-13 WO PCT/IB2012/054775 patent/WO2013038362A1/en not_active Ceased
- 2012-09-13 KR KR1020147009795A patent/KR20140077916A/ko not_active Withdrawn
- 2012-09-13 JP JP2014530361A patent/JP5957526B2/ja not_active Expired - Fee Related
- 2012-09-14 AR ARP120103386A patent/AR087868A1/es unknown
- 2012-09-14 TW TW101133879A patent/TW201319067A/zh unknown
-
2015
- 2015-05-19 US US14/716,159 patent/US9474762B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014526499A5 (https=) | ||
| JP7624985B2 (ja) | Ｐｒｍｔ５阻害剤の組合せ医薬 | |
| KR102534028B1 (ko) | 트리아졸로피리미딘 화합물 및 그의 용도 | |
| ES2826950T3 (es) | Métodos para tratar cáncer y afecciones no neoplásicas | |
| IL297481A (en) | Halogenated heteroaryls and other heterocyclic kinase inhibitors, and uses thereof | |
| JP2017530999A5 (https=) | ||
| JP2020526499A5 (https=) | ||
| JP2019514878A5 (https=) | ||
| BR112020005368A2 (pt) | formulações compreendendo 6-(2-hidróxi-2-metilpropóxi)-4-(6-(6-((6-metoxipiridin-3-il)metil)-3,6-diazabiciclo[3.1.1]heptan-3-il) piridin-3-il)pirazolo[1,5-a]piridina-3-carbonitrila | |
| RU2014151009A (ru) | Пиразолопиримидоновые и пиразолопиридоновые ингибиторы танкиразы | |
| JP2009529047A5 (https=) | ||
| JP2014513110A5 (https=) | ||
| JP2013539777A5 (https=) | ||
| CA2683641A1 (en) | Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha | |
| JP2014517050A5 (https=) | ||
| BR112012022650B1 (pt) | Derivados de imidazo[1,2-a]pirazina, seu uso no tratamento ou na prevenção de distúrbios e doenças neurológicos, psiquiátricos ou metabólicos, composição farmacêutica que os compreende processo de preparação da mesma | |
| SI2790705T1 (en) | Use of activity inhibitors or PI3K function | |
| EP3691620A1 (en) | P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd | |
| HRP20210931T1 (hr) | Alkil-amin harminski derivati za poticanje rasta kostiju | |
| RU2019123319A (ru) | Пиразолопиримидины и способы их применения | |
| WO2020206035A1 (en) | Treatment of cdk4/6 inhibitor resistant neoplastic disorders | |
| EP3735247A1 (en) | Heterocyclic compounds for the treatment of abnormal cellular proliferation | |
| RU2015120217A (ru) | Замещенные 1,6-нафтиридины | |
| JP2019505595A5 (https=) | ||
| WO2015091531A1 (en) | Imidazolopyrimidin-2-yl derivatives as jak inhibitors |